{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:22:19Z","timestamp":1791253339199,"version":"4.1.0"},"reference-count":165,"publisher":"Japan Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2010]]},"DOI":"10.1507\/endocrj.k10e-077","type":"journal-article","created":{"date-parts":[[2010,4,13]],"date-time":"2010-04-13T22:30:16Z","timestamp":1271197816000},"page":"359-372","source":"Crossref","is-referenced-by-count":240,"title":["The role of gut hormones and the hypothalamus in appetite regulation"],"prefix":"10.1507","volume":"57","author":[{"given":"Keisuke","family":"Suzuki","sequence":"first","affiliation":[{"name":"Section of Investigative Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A","family":"Simpson","sequence":"additional","affiliation":[{"name":"Section of Investigative Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S","family":"Minnion","sequence":"additional","affiliation":[{"name":"Section of Investigative Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyceline C","family":"Shillito","sequence":"additional","affiliation":[{"name":"Section of Investigative Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R","family":"Bloom","sequence":"additional","affiliation":[{"name":"Section of Investigative Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Zaninotto P, Head J, Stamatakis E, Wardle H, Mindell J (2009) Trends in obesity among adults in England from 1993 to 2004 by age and social class and projections of prevalence to 2012. <i>J Epidemiol Community Health <\/i>63: 140-146.","DOI":"10.1136\/jech.2008.077305"},{"key":"2","unstructured":"2. WHO (2008) Obesity."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Matsushita Y, Takahashi Y, Mizoue T, Inoue M, Noda M, Tsugane S (2008) Overweight and obesity trends among Japanese adults: a 10-year follow-up of the JPHC Study. <i>Int J Obes (Lond) <\/i>32: 1861-1867.","DOI":"10.1038\/ijo.2008.188"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm E, Colditz GA (2001) Impact of overweight on the risk of developing common chronic diseases during a 10-year period. <i>Arch Intern Med <\/i>161: 1581-1586.","DOI":"10.1001\/archinte.161.13.1581"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.16.1523"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn565"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Shah N, Roux F (2009) The relationship of obesity and obstructive sleep apnea. <i>Clin Chest Med <\/i>30: 455-465, vii.","DOI":"10.1016\/j.ccm.2009.05.012"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, Tuomilehto J (2006) Body mass index and the risk of Parkinson disease. <i>Neurology <\/i>67: 1955-1959.","DOI":"10.1212\/01.wnl.0000247052.18422.e5"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Whitmer RA, Gunderson EP, Quesenberry CP, Jr., Zhou J, Yaffe K (2007) Body mass index in midlife and risk of Alzheimer disease and vascular dementia. <i>Curr Alzheimer Res <\/i>4: 103-109.","DOI":"10.2174\/156720507780362047"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2002.00790.x"},{"issue":"7","key":"11","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1210\/er.2006-0040","volume":"27","author":"FAROOQI I. SADAF","year":"2006","ISSN":"https:\/\/id.crossref.org\/issn\/0163-769X","issn-type":"print"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Hinney A, Vogel CI, Hebebrand J (2010) From monogenic to polygenic obesity: recent advances. <i>Eur Child Adolesc Psychiatry <\/i>in press.","DOI":"10.1007\/978-1-60327-874-4_5"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra012586"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Brolin RE (2002) Bariatric surgery and long-term control of morbid obesity. <i>JAMA <\/i>288: 2793-2796.","DOI":"10.1001\/jama.288.22.2793"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012908"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2009.79"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, Lonroth H, Fandriks L, Ghatei MA, Bloom SR, Olbers T (2007) Gut hormones as mediators of appetite and weight loss after Rouxen-Y gastric bypass. <i>Ann Surg <\/i>246: 780-785.","DOI":"10.1097\/SLA.0b013e3180caa3e3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Chaudhri OB, Wynne K, Bloom SR (2008) Can gut hormones control appetite and prevent obesity? <i>Diabetes Care <\/i>31 Suppl 2: S284-289.","DOI":"10.2337\/dc08-s269"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Field BC, Chaudhri OB, Bloom SR (2009) Obesity treatment: novel peripheral targets. <i>Br J Clin Pharmacol <\/i>68: 830-843.","DOI":"10.1111\/j.1365-2125.2009.03522.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Mayer J, Thomas DW (1967) Regulation of food intake and obesity. <i>Science <\/i>156: 328-337.","DOI":"10.1126\/science.156.3773.328"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)62338-9"},{"issue":"6778","key":"22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/35007534","volume":"404","author":"SCHWARTZ M W","year":"2000","ISSN":"https:\/\/id.crossref.org\/issn\/0028-0836","issn-type":"print"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81865-6"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tao YX (2005) Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. <i>Mol Cell Endocrinol <\/i>239: 1-14.","DOI":"10.1016\/j.mce.2005.04.012"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1038\/ng.140"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1038\/79254"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(00)02386-6"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1038\/29993"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Abbott CR, Rossi M, Wren AM, Murphy KG, Kennedy AR, Stanley SA, Zollner AN, Morgan DG, Morgan I, Ghatei MA, Small CJ, Bloom SR (2001) Evidence of an orexigenic role for cocaine- and amphetamine-regulated transcript after administration into discrete hypothalamic nuclei. <i>Endocrinology <\/i>142: 3457-3463.","DOI":"10.1210\/endo.142.8.8304"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Clark JT, Kalra PS, Crowley WR, Kalra SP (1984) Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. <i>Endocrinology <\/i>115: 427-429.","DOI":"10.1210\/endo-115-1-427"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF (1986) Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. <i>Peptides <\/i>7: 1189-1192.","DOI":"10.1016\/0196-9781(86)90149-X"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(04)00074-1"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1210\/en.139.10.4428"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Belgardt BF, Okamura T, Bruning JC (2009) Hormone and glucose signalling in POMC and AgRP neurons. <i>J Physiol <\/i>587: 5305-5314.","DOI":"10.1113\/jphysiol.2009.179192"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9384(81)90366-8"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1677\/joe.1.05866"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1038\/nn1073"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Unger TJ, Calderon GA, Bradley LC, Sena-Esteves M, Rios M (2007) Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. <i>J Neurosci <\/i>27: 14265-14274.","DOI":"10.1523\/JNEUROSCI.3308-07.2007"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Bailey EF (2008) A tasty morsel: the role of the dorsal vagal complex in the regulation of food intake and swallowing. Focus on &ldquo;BDNF\/TrkB signaling interacts with GABAergic system to inhibit rhythmic swallowing in the rat,&rdquo; by Bariohay <i>et al<\/i>. <i>Am J Physiol Regul Integr Comp Physiol <\/i>295: R1048-1049.","DOI":"10.1152\/ajpregu.90701.2008"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1016\/S0899-9007(00)00464-0"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Schwartz GJ, Salorio CF, Skoglund C, Moran TH (1999) Gut vagal afferent lesions increase meal size but do not block gastric preload-induced feeding suppression. <i>Am J Physiol <\/i>276: R1623-1629.","DOI":"10.1152\/ajpregu.1999.276.6.R1623"},{"key":"42","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(96)00675-6"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Burdyga G, Spiller D, Morris R, Lal S, Thompson DG, Saeed S, Dimaline R, Varro A, Dockray GJ (2002) Expression of the leptin receptor in rat and human nodose ganglion neurones. <i>Neuroscience <\/i>109: 339-347.","DOI":"10.1016\/S0306-4522(01)00474-2"},{"key":"44","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-1266"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, Kigoshi T, Nakayama K, Uchida K (2004) Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. <i>Auton Neurosci <\/i>110: 36-43.","DOI":"10.1016\/j.autneu.2003.11.001"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Nelson DW, Sharp JW, Brownfield MS, Raybould HE, Ney DM (2007) Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat. <i>Endocrinology <\/i>148: 1954-1962.","DOI":"10.1210\/en.2006-1232"},{"key":"47","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.35954"},{"key":"48","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50020"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.1006\/frne.2001.0224"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Ellacott KL, Halatchev IG, Cone RD (2006) Characterization of leptin-responsive neurons in the caudal brainstem. <i>Endocrinology <\/i>147: 3190-3195.","DOI":"10.1210\/en.2005-0877"},{"key":"51","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresrev.2005.10.004"},{"issue":"2","key":"52","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0022-3565(24)37432-4","volume":"285","year":"1998","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3565","issn-type":"print"},{"key":"53","doi-asserted-by":"publisher","DOI":"10.1038\/35071088"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Rehfeld JF (1998) The new biology of gastrointestinal hormones. <i>Physiol Rev <\/i>78: 1087-1108.","DOI":"10.1152\/physrev.1998.78.4.1087"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Martin CK, Bellanger DE, Rau KK, Coulon S, Greenway FL (2007) Safety of the Ullorex oral intragastric balloon for the treatment of obesity. <i>J Diabetes Sci Technol <\/i>1: 574-581.","DOI":"10.1177\/193229680700100416"},{"key":"56","unstructured":"56. Rigaud D, Trostler N, Rozen R, Vallot T, Apfelbaum M (1995) Gastric distension, hunger and energy intake after balloon implantation in severe obesity. <i>Int J Obes Relat Metab Disord <\/i>19: 489-495."},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Fernandes M, Atallah AN, Soares BG, Humberto S, Guimaraes S, Matos D, Monteiro L, Richter B (2007) Intragastric balloon for obesity. <i>Cochrane Database Syst Rev<\/i>: CD004931.","DOI":"10.1002\/14651858.CD004931.pub2"},{"key":"58","doi-asserted-by":"publisher","DOI":"10.1038\/285417a0"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Lin S, Boey D, Herzog H (2004) NPY and Y receptors: lessons from transgenic and knockout models. <i>Neuropeptides <\/i>38: 189-200.","DOI":"10.1016\/j.npep.2004.05.005"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Eberlein GA, Eysselein VE, Schaeffer M, Layer P, Grandt D, Goebell H, Niebel W, Davis M, Lee TD, Shively JE, Reeve JR, Jr (1989) A new molecular form of PYY: structural characterization of human PYY(3-36) and PYY(1-36). <i>Peptides <\/i>10: 797-803.","DOI":"10.1016\/0196-9781(89)90116-2"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Keire DA, Bowers CW, Solomon TE, Reeve JR, Jr. (2002) Structure and receptor binding of PYY analogs. <i>Peptides <\/i>23: 305-321.","DOI":"10.1016\/S0196-9781(01)00602-7"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR (1985) Human distribution and release of a putative new gut hormone, peptide YY. <i>Gastroenterology <\/i>89: 1070-1077.","DOI":"10.1016\/0016-5085(85)90211-2"},{"key":"63","doi-asserted-by":"publisher","DOI":"10.1038\/nature00887"},{"key":"64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030204"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Boey D, Lin S, Enriquez RF, Lee NJ, Slack K, Couzens M, Baldock PA, Herzog H, Sainsbury A (2008) PYY transgenic mice are protected against diet-induced and genetic obesity. <i>Neuropeptides <\/i>42: 19-30.","DOI":"10.1016\/j.npep.2007.11.003"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL (2005) Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. <i>Endocrinology <\/i>146: 3748-3756.","DOI":"10.1210\/en.2005-0473"},{"key":"67","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0409"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Pfluger PT, Kampe J, Castaneda TR, Vahl T, D&rsquo;Alessio DA, Kruthaupt T, Benoit SC, Cuntz U, Rochlitz HJ, Moehlig M, Pfeiffer AF, Koebnick C, Weickert MO, Otto B, Spranger J, Tschop MH (2007) Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. <i>J Clin Endocrinol Metab <\/i>92: 583-588.","DOI":"10.1210\/jc.2006-1425"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Alvarez Bartolome M, Borque M, Martinez-Sarmiento J, Aparicio E, Hernandez C, Cabrerizo L, Fernandez-Represa JA (2002) Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. <i>Obes Surg <\/i>12: 324-327.","DOI":"10.1381\/096089202321088084"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Misra M, Miller KK, Tsai P, Gallagher K, Lin A, Lee N, Herzog DB, Klibanski A (2006) Elevated peptide YY levels in adolescent girls with anorexia nervosa. <i>J Clin Endocrinol Metab <\/i>91: 1027-1033.","DOI":"10.1210\/jc.2005-1878"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Ashby D, Bloom SR (2007) Recent progress in PYY research--an update report for 8th NPY meeting. <i>Peptides <\/i>28: 198-202.","DOI":"10.1016\/j.peptides.2006.10.019"},{"key":"72","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2005.03.011"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Morley JE, Levine AS, Grace M, Kneip J (1985) Peptide YY (PYY), a potent orexigenic agent. <i>Brain Res <\/i>341: 200-203.","DOI":"10.1016\/0006-8993(85)91490-8"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Stanley BG, Daniel DR, Chin AS, Leibowitz SF (1985) Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion. <i>Peptides <\/i>6: 1205-1211.","DOI":"10.1016\/0196-9781(85)90452-8"},{"key":"75","doi-asserted-by":"publisher","DOI":"10.1210\/en.141.3.1011"},{"key":"76","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00216-6"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Parker RM, Herzog H (1999) Regional distribution of Y-receptor subtype mRNAs in rat brain. <i>Eur J Neurosci <\/i>11: 1431-1448.","DOI":"10.1046\/j.1460-9568.1999.00553.x"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Whitcomb DC, Taylor IL, Vigna SR (1990) Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain. <i>Am J Physiol <\/i>259: G687-691.","DOI":"10.1152\/ajpgi.1990.259.4.G687"},{"key":"79","unstructured":"79. Jorde R, Burhol PG (1984) Fasting and postprandial plasma pancreatic polypeptide (PP) levels in obesity. <i>Int J Obes <\/i>8: 393-397."},{"key":"80","doi-asserted-by":"publisher","DOI":"10.1016\/0167-0115(92)90007-H"},{"issue":"5","key":"81","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1055\/s-2007-1010817","volume":"20","year":"1988","ISSN":"https:\/\/id.crossref.org\/issn\/0018-5043","issn-type":"print"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Lassmann V, Vague P, Vialettes B, Simon MC (1980) Low plasma levels of pancreatic polypeptide in obesity. <i>Diabetes <\/i>29: 428-430.","DOI":"10.2337\/diab.29.6.428"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Asakawa A, Inui A, Ueno N, Fujimiya M, Fujino MA, Kasuga M (1999) Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice. <i>Peptides <\/i>20: 1445-1448.","DOI":"10.1016\/S0196-9781(99)00155-2"},{"key":"84","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70293-3"},{"key":"85","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030630"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Holst JJ (2004) On the physiology of GIP and GLP-1. <i>Horm Metab Res <\/i>36: 747-754.","DOI":"10.1055\/s-2004-826158"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Tang-Christensen M, Vrang N, Larsen PJ (2001) Glucagon-like peptide containing pathways in the regulation of feeding behaviour. <i>Int J Obes Relat Metab Disord <\/i>25 Suppl 5: S42-47.","DOI":"10.1038\/sj.ijo.0801912"},{"key":"88","doi-asserted-by":"publisher","DOI":"10.1016\/0167-0115(95)00167-0"},{"key":"89","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.357"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Deacon CF (2004) Circulation and degradation of GIP and GLP-1. <i>Horm Metab Res <\/i>36: 761-765.","DOI":"10.1055\/s-2004-826160"},{"key":"91","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1993.tb17986.x"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Vilsboll T, Agerso H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. <i>J Clin Endocrinol Metab <\/i>88: 220-224.","DOI":"10.1210\/jc.2002-021053"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. <i>Diabetes <\/i>43: 535-539.","DOI":"10.2337\/diab.43.4.535"},{"key":"94","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006"},{"issue":"2","key":"95","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1055\/s-2007-978985","volume":"29","year":"1997","ISSN":"https:\/\/id.crossref.org\/issn\/0018-5043","issn-type":"print"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. Vahl TP, Drazen DL, Seeley RJ, D&rsquo;Alessio DA, Woods SC (2010) Meal-anticipatory glucagon-like peptide-1 secretion in rats. <i>Endocrinology <\/i>151: 569-575.","DOI":"10.1210\/en.2009-1002"},{"key":"97","unstructured":"97. Cummings DE, Overduin J (2007) Gastrointestinal regulation of food intake. <i>J Clin Invest <\/i>117: 13-23."},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, Astrup A (2001) A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. <i>J Clin Endocrinol Metab <\/i>86: 4382-4389.","DOI":"10.1210\/jc.86.9.4382"},{"issue":"11","key":"99","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","volume":"267","year":"1992","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9258","issn-type":"print"},{"key":"100","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.5.1092"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). <i>Lancet <\/i>374: 39-47.","DOI":"10.1016\/S0140-6736(09)60659-0"},{"key":"102","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(98)00136-2"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103. Schmidt PT, Naslund E, Gryback P, Jacobsson H, Hartmann B, Holst JJ, Hellstrom PM (2003) Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. <i>Regul Pept <\/i>116: 21-25.","DOI":"10.1016\/S0167-0115(03)00175-7"},{"key":"104","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.15.7911"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105. Wallis K, Walters JR, Forbes A (2007) Review article: glucagon-like peptide 2--current applications and future directions. <i>Aliment Pharmacol Ther <\/i>25: 365-372.","DOI":"10.1111\/j.1365-2036.2006.03193.x"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106. Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG (2009) Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn&rsquo;s disease. <i>Inflamm Bowel Dis <\/i>","DOI":"10.1002\/ibd.21117"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107. Nagell CF, Wettergren A, Pedersen JF, Mortensen D, Holst JJ (2004) Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. <i>Scand J Gastroenterol <\/i>39: 353-358.","DOI":"10.1080\/00365520410004424"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108. Ghatei MA, Uttenthal LO, Christofides ND, Bryant MG, Bloom SR (1983) Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. <i>J Clin Endocrinol Metab <\/i>57: 488-495.","DOI":"10.1210\/jcem-57-3-488"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, Bloom SR (2003) Oxyntomodulin suppresses appetite and reduces food intake in humans. <i>J Clin Endocrinol Metab <\/i>88: 4696-4701.","DOI":"10.1210\/jc.2003-030421"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, Ghatei MA, Bloom SR (2001) Oxyntomodulin inhibits food intake in the rat. <i>Endocrinology <\/i>142: 4244-4250.","DOI":"10.1210\/endo.142.10.8430"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, Bloom SR (2006) Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. <i>Int J Obes (Lond) <\/i>30: 1729-1736.","DOI":"10.1038\/sj.ijo.0803344"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, Bloom SR (2004) Peripheral oxyntomodulin reduces food intake and body weight gain in rats. <i>Endocrinology <\/i>145: 2687-2695.","DOI":"10.1210\/en.2003-1338"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113. Baggio LL, Huang Q, Brown TJ, Drucker DJ (2004) Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. <i>Gastroenterology <\/i>127: 546-558.","DOI":"10.1053\/j.gastro.2004.04.063"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114. Sowden GL, Drucker DJ, Weinshenker D, Swoap SJ (2007) Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. <i>Am J Physiol Regul Integr Comp Physiol <\/i>292: R962-970.","DOI":"10.1152\/ajpregu.00405.2006"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115. Ban K, Kim KH, Cho CK, Sauve M, Diamandis EP, Backx PH, Drucker DJ, Husain M (2010) Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor. <i>Endocrinology <\/i>in press.","DOI":"10.1210\/en.2009-1197"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116. Druce MR, Minnion JS, Field BC, Patel SR, Shillito JC, Tilby M, Beale KE, Murphy KG, Ghatei MA, Bloom SR (2009) Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs. <i>Endocrinology <\/i>150: 1712-1722.","DOI":"10.1210\/en.2008-0828"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117. Chan EK, Mackey MA, Snover DC, Schneider PD, Rucker RD, Jr., Allen CE, Buchwald H (1984) Suppression of weight gain by glucagon in obese Zucker rats. <i>Exp Mol Pathol <\/i>40: 320-327.","DOI":"10.1016\/0014-4800(84)90049-2"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118. Geary N, Le Sauter J, Noh U (1993) Glucagon acts in the liver to control spontaneous meal size in rats. <i>Am J Physiol <\/i>264: R116-122.","DOI":"10.1152\/ajpregu.1993.264.1.R116"},{"key":"119","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.209"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zhang X, Sountis MM, Santoprete A, Capito E, Chicchi GG, Thornberry N, Bianchi E, Pessi A, Marsh DJ, SinhaRoy R (2009) Glucagon-like peptide 1\/glucagon receptor dual agonism reverses obesity in mice. <i>Diabetes <\/i>58: 2258-2266.","DOI":"10.2337\/db09-0278"},{"key":"121","doi-asserted-by":"publisher","DOI":"10.1038\/45230"},{"key":"122","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.8.1714"},{"key":"123","doi-asserted-by":"publisher","DOI":"10.1038\/35051587"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124. Tschop M, Smiley DL, Heiman ML (2000) Ghrelin induces adiposity in rodents. <i>Nature <\/i>407: 908-913.","DOI":"10.1038\/35038090"},{"key":"125","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1450669"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126. le Roux CW, Patterson M, Vincent RP, Hunt C, Ghatei MA, Bloom SR (2005) Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. <i>J Clin Endocrinol Metab <\/i>90: 1068-1071.","DOI":"10.1210\/jc.2004-1216"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127. Wang L, Saint-Pierre DH, Tache Y (2002) Peripheral ghrelin selectively increases Fos expression in neuropeptide Y - synthesizing neurons in mouse hypothalamic arcuate nucleus. <i>Neurosci Lett <\/i>325: 47-51.","DOI":"10.1016\/S0304-3940(02)00241-0"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128. Chen HY, Trumbauer ME, Chen AS, Weingarth DT, Adams JR, Frazier EG, Shen Z, Marsh DJ, Feighner SD, Guan XM, Ye Z, Nargund RP, Smith RG, Van der Ploeg LH, Howard AD, MacNeil DJ, Qian S (2004) Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. <i>Endocrinology <\/i>145: 2607-2612.","DOI":"10.1210\/en.2003-1596"},{"key":"129","doi-asserted-by":"publisher","DOI":"10.1210\/en.143.1.155"},{"key":"130","doi-asserted-by":"publisher","DOI":"10.1037\/h0034870"},{"key":"131","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111809"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132. Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP (1981) C-terminal octapeptide of cholecystokinin decreases food intake in man. <i>Am J Clin Nutr <\/i>34: 154-160.","DOI":"10.1093\/ajcn\/34.2.154"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133. Wank SA (1995) Cholecystokinin receptors. <i>Am J Physiol <\/i>269: G628-646.","DOI":"10.1152\/ajpgi.1995.269.5.G628"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134. Moran TH, Baldessarini AR, Salorio CF, Lowery T, Schwartz GJ (1997) Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. <i>Am J Physiol <\/i>272: R1245-1251.","DOI":"10.1152\/ajpregu.1997.272.4.R1245"},{"key":"135","doi-asserted-by":"crossref","unstructured":"135. Moran TH, Katz LF, Plata-Salaman CR, Schwartz GJ (1998) Disordered food intake and obesity in rats lacking cholecystokinin A receptors. <i>Am J Physiol <\/i>274: R618-625.","DOI":"10.1152\/ajpregu.1998.274.3.R618"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136. West DB, Fey D, Woods SC (1984) Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. <i>Am J Physiol <\/i>246: R776-787.","DOI":"10.1152\/ajpregu.1984.246.5.R776"},{"key":"137","doi-asserted-by":"publisher","DOI":"10.1038\/302703a0"},{"key":"138","doi-asserted-by":"crossref","unstructured":"138. Reda TK, Geliebter A, Pi-Sunyer FX (2002) Amylin, food intake, and obesity. <i>Obes Res <\/i>10: 1087-1091.","DOI":"10.1038\/oby.2002.147"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139. Reinehr T, de Sousa G, Niklowitz P, Roth CL (2007) Amylin and its relation to insulin and lipids in obese children before and after weight loss. <i>Obesity (Silver Spring) <\/i>15: 2006-2011.","DOI":"10.1038\/oby.2007.239"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, Woods SC (2000) Amylin: a novel action in the brain to reduce body weight. <i>Endocrinology <\/i>141: 850-853.","DOI":"10.1210\/endo.141.2.7378"},{"key":"141","doi-asserted-by":"crossref","unstructured":"141. Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG (1998) Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group. <i>Diabetes Care <\/i>21: 987-993.","DOI":"10.2337\/diacare.21.6.987"},{"key":"142","doi-asserted-by":"crossref","unstructured":"142. Polonsky KS, Given BD, Van Cauter E (1988) Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. <i>J Clin Invest <\/i>81: 442-448.","DOI":"10.1172\/JCI113339"},{"key":"143","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1985.tb07167.x"},{"key":"144","doi-asserted-by":"crossref","unstructured":"144. Marks JL, Porte D, Jr., Stahl WL, Baskin DG (1990) Localization of insulin receptor mRNA in rat brain by in situ hybridization. <i>Endocrinology <\/i>127: 3234-3236.","DOI":"10.1210\/endo-127-6-3234"},{"key":"145","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(01)00780-8"},{"key":"146","doi-asserted-by":"crossref","unstructured":"146. Porte D, Jr., Woods SC (1981) Regulation of food intake and body weight in insulin. <i>Diabetologia <\/i>20 Suppl: 274-280.","DOI":"10.1007\/BF00254493"},{"key":"147","doi-asserted-by":"publisher","DOI":"10.1038\/nn861"},{"key":"148","doi-asserted-by":"crossref","unstructured":"148. Schwartz MW, Sipols AJ, Marks JL, Sanacora G, White JD, Scheurink A, Kahn SE, Baskin DG, Woods SC, Figlewicz DP (1992) Inhibition of hypothalamic neuropeptide Y gene expression by insulin. <i>Endocrinology <\/i>130: 3608-3616.","DOI":"10.1210\/endo.130.6.1597158"},{"key":"149","doi-asserted-by":"crossref","unstructured":"149. Benoit SC, Air EL, Coolen LM, Strauss R, Jackman A, Clegg DJ, Seeley RJ, Woods SC (2002) The catabolic action of insulin in the brain is mediated by melanocortins. <i>J Neurosci <\/i>22: 9048-9052.","DOI":"10.1523\/JNEUROSCI.22-20-09048.2002"},{"key":"150","doi-asserted-by":"crossref","unstructured":"150. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. <i>Nature <\/i>372: 425-432.","DOI":"10.1038\/372425a0"},{"key":"151","doi-asserted-by":"crossref","unstructured":"151. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. <i>N Engl J Med <\/i>334: 292-295.","DOI":"10.1056\/NEJM199602013340503"},{"key":"152","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.2.453"},{"key":"153","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119717"},{"key":"154","doi-asserted-by":"crossref","unstructured":"154. Korbonits M, Trainer PJ, Little JA, Edwards R, Kopelman PG, Besser GM, Svec F, Grossman AB (1997) Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary-adrenal activity. <i>Clin Endocrinol (Oxf) <\/i>46: 751-757.","DOI":"10.1046\/j.1365-2265.1997.1820979.x"},{"key":"155","doi-asserted-by":"crossref","unstructured":"155. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM (1996) Leptin enters the brain by a saturable system independent of insulin. <i>Peptides <\/i>17: 305-311.","DOI":"10.1016\/0196-9781(96)00025-3"},{"key":"156","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.4.828"},{"key":"157","doi-asserted-by":"crossref","unstructured":"157. Sahu A (2003) Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance. <i>Front Neuroendocrinol <\/i>24: 225-253.","DOI":"10.1016\/j.yfrne.2003.10.001"},{"key":"158","doi-asserted-by":"crossref","unstructured":"158. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F (1995) Effects of the obese gene product on body weight regulation in ob\/ob mice. <i>Science <\/i>269: 540-543.","DOI":"10.1126\/science.7624776"},{"key":"159","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.13.7001"},{"key":"160","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81294-5"},{"key":"161","doi-asserted-by":"publisher","DOI":"10.1007\/BF00429772"},{"key":"162","doi-asserted-by":"crossref","unstructured":"162. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM (1995) Weight-reducing effects of the plasma protein encoded by the obese gene. <i>Science <\/i>269: 543-546.","DOI":"10.1126\/science.7624777"},{"key":"163","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200215693"},{"key":"164","doi-asserted-by":"crossref","unstructured":"164. Munzberg H (2010) Leptin-Signaling Pathways and Leptin Resistance. <i>Forum Nutr <\/i>63: 123-132.","DOI":"10.1159\/000264400"},{"key":"165","doi-asserted-by":"crossref","unstructured":"165. Banks WA (2001) Anorectic effects of circulating cytokines: role of the vascular blood-brain barrier. <i>Nutrition <\/i>17: 434-437.","DOI":"10.1016\/S0899-9007(01)00507-X"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/endocrj\/57\/5\/57_K10E-077\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:01:22Z","timestamp":1739991682000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/endocrj\/57\/5\/57_K10E-077\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":165,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.k10e-077","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010]]}}}